BNP Paribas Financial Markets’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $119K | Sell |
31,712
-574,563
| -95% | -$2.19M | ﹤0.01% | 4465 |
|
|
2026
Q1 | $2.85M | Buy |
606,275
+603,450
| +21,361% | +$3.06M | ﹤0.01% | 2449 |
|
|
2025
Q4 | $12K | Buy |
2,825
+2,808
| +16,518% | +$10.7K | ﹤0.01% | 5122 |
|
|
2025
Q3 | $54 | Hold |
17
| – | – | ﹤0.01% | 5467 |
|
|
2025
Q2 | $39 | Hold |
17
| – | – | ﹤0.01% | 5369 |
|
|
2025
Q1 | $11 | Sell |
17
-61
| -78% | -$47 | ﹤0.01% | 5336 |
|
|
2024
Q4 | $80 | Sell |
78
-116
| -60% | -$125 | ﹤0.01% | 5291 |
|
|
2024
Q3 | $229 | Buy |
194
+116
| +149% | +$147 | ﹤0.01% | 4036 |
|
|
2024
Q2 | $95 | Hold |
78
| – | – | ﹤0.01% | 3972 |
|
|
2024
Q1 | $170 | Hold |
78
| – | – | ﹤0.01% | 3953 |
|
|
2023
Q4 | $121 | Sell |
78
-158
| -67% | -$208 | ﹤0.01% | 3944 |
|
|
2023
Q3 | $304 | Buy |
236
+61
| +35% | +$96 | ﹤0.01% | 3810 |
|
|
2023
Q2 | $301 | Buy |
175
+158
| +929% | +$262 | ﹤0.01% | 3814 |
|
|
2023
Q1 | $26 | Sell |
17
-3
| -15% | -$7 | ﹤0.01% | 3807 |
|
|
2022
Q4 | $32 | Sell |
20
-513
| -96% | -$759 | ﹤0.01% | 3989 |
|
|
2022
Q3 | $773 | Sell |
533
-18,785
| -97% | -$28.9K | ﹤0.01% | 4469 |
|
|
2022
Q2 | $35.4K | Buy |
19,318
+13,864
| +254% | +$26.5K | ﹤0.01% | 3631 |
|
|
2022
Q1 | $14.6K | Sell |
5,454
-7,970
| -59% | -$30.6K | ﹤0.01% | 3759 |
|
|
2021
Q4 | $58.1K | Buy |
13,424
+1,805
| +16% | +$10.6K | ﹤0.01% | 3715 |
|
|
2021
Q3 | $59.1K | Buy |
11,619
+9,426
| +430% | +$50.5K | ﹤0.01% | 3467 |
|
|
2021
Q2 | $13.9K | Sell |
2,193
-14,736
| -87% | -$115K | ﹤0.01% | 3639 |
|
|
2021
Q1 | $131K | Buy |
16,929
+11,267
| +199% | +$89.2K | ﹤0.01% | 3233 |
|
|
2020
Q4 | $37.1K | Sell |
5,662
-4,756
| -46% | -$34K | ﹤0.01% | 3683 |
|
|
2020
Q3 | $69.3K | Buy |
10,418
+6,072
| +140% | +$45K | ﹤0.01% | 3304 |
|
|
2020
Q2 | $36.2K | Sell |
4,346
-9,652
| -69% | -$89.6K | ﹤0.01% | 3167 |
|
|
2020
Q1 | $107K | Buy |
13,998
+8,671
| +163% | +$60.5K | ﹤0.01% | 3166 |
|
|
2019
Q4 | $44.3K | Sell |
5,327
-1,767
| -25% | -$11.9K | ﹤0.01% | 3709 |
|
|
2019
Q3 | $52.4K | Buy |
7,094
+2,126
| +43% | +$21K | ﹤0.01% | 3456 |
|
|
2019
Q2 | $55.7K | Sell |
4,968
-4,291
| -46% | -$45K | ﹤0.01% | 3354 |
|
|
2019
Q1 | $99.5K | Buy |
9,259
+9,248
| +84,073% | +$137K | ﹤0.01% | 3131 |
|
|
2018
Q4 | $166 | Sell |
11
-1,211
| -99% | -$18K | ﹤0.01% | 4122 |
|
|
2018
Q3 | $22.6K | Hold |
1,222
| – | – | ﹤0.01% | 3363 |
|
|
2018
Q2 | $27.9K | Sell |
1,222
-4,899
| -80% | -$125K | ﹤0.01% | 3361 |
|
|
2018
Q1 | $174K | Buy |
6,121
+50
| +0.8% | +$1.43K | ﹤0.01% | 2873 |
|
|
2017
Q4 | $128K | Buy |
6,071
+2,969
| +96% | +$61.6K | ﹤0.01% | 3174 |
|
|
2017
Q3 | $56.4K | Sell |
3,102
-177
| -5% | -$2.76K | ﹤0.01% | 3091 |
|
|
2017
Q2 | $50.8K | Buy |
3,279
+3,039
| +1,266% | +$45.8K | ﹤0.01% | 3188 |
|
|
2017
Q1 | $4.14K | Sell |
240
-978
| -80% | -$12.9K | ﹤0.01% | 3352 |
|
|
2016
Q4 | $13.4K | Sell |
1,218
-202
| -14% | -$2.45K | ﹤0.01% | 3335 |
|
|
2016
Q3 | $22.3K | Buy |
1,420
+577
| +68% | +$6.98K | ﹤0.01% | 2831 |
|
|
2016
Q2 | $8.61K | Buy |
+843
| New | +$9.62K | ﹤0.01% | 2983 |
|
|
2016
Q1 | – | Sell |
-1,376
| Closed | -$28.7K | – | 2761 |
|
|
2015
Q4 | $28.7K | Buy |
+1,376
| New | +$21.8K | ﹤0.01% | 3144 |
|
Other funds holding CTMX
VCM
BBA
EC
NI
EP
BNP Paribas Financial Markets's CTMX Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its CytomX Therapeutics (CTMX) stake by 95% in Q2 2026, selling an estimated $2.19M and leaving 31,712 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #4465.
BNP Paribas Financial Markets first reported a position in CTMX in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.85M in Q1 2026. 161 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.
- BNP Paribas Financial Markets held 31,712 shares of CytomX Therapeutics worth $119K as of Q2 2026.
- BNP Paribas Financial Markets sold 574,563 CytomX Therapeutics shares in Q2 2026, an estimated $2.19M.
- CytomX Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4465 holding.
- BNP Paribas Financial Markets first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 42 quarters since.
- BNP Paribas Financial Markets's CytomX Therapeutics position peaked at $2.85M in Q1 2026.
- 161 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.